Forskrivning av antihypertensive legemidler 1975-2010

Tidsskrift for den Norske Laegeforening

Volumn 132, Issue 10, 2012, Pages 1224-1228

  Blix, Hege Salvesen ^a   Landmark, Knud ^b   Selmer, Randi ^a   Reikvam, Åsmund ^b  

^a Nasjonalt Folkehelseinstitutt ^*  (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NORWAY; PRESCRIPTION; REGISTER; STATISTICS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CHILD; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NORWAY; REGISTRIES; THIAZIDES;

EID: 84867684204     PISSN: 00292001     EISSN: 08077096     Source Type: Journal    
DOI: 10.4045/tidsskr.11.0984     Document Type: Article

References (23)

1. Holmen J, Forsdahl A, Kvamme JI et al. Høyt blodtrykk. NSAMs handlingsprogram for allmennpraksis. Rapport 11. Oslo, Gruppe for helsetjenesteeffektivisering, 1986.
2. Holmen J, Aursnes I, Forsdahl A et al. Høyt blodtrykk. NSAMs handlingsprogram. Rapport U3, 1993. Verdal, Samfunnsmedisinsk forskningssenter, Folkehelsa, 1993.
3. Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension, ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007, 25, 1751-62.
4. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure, the JNC 7 report. JAMA 2003, 289, 2560-72.
5. Helsedirektoratet. Nasjonale retningslinjer for individuell primærforebygging av hjerte- og karsykdommer. IS-1550. www.helsedirektoratet.no (9.2.2012).
6. Medicines consumption in the Nordic countries 1999-2003. København, Nordic Medico-Statistical Committee, NOMESCO, 2004.
7. Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs, its extent and possible explanations. BMC Health Serv Res 2005, 5, 21.
8. Statens legemiddelverk. Tiazid som førstevalg ved hypertensjon. Nytt om legemidler 2004, nr. 2, 6.
9. Statens legemiddelverk. Vedtak, Endring i refusjonsvilkår for blodtrykksenkende midler, forskrift av 28. juni 2007 nr 814, 10. desember 2009. Oslo, Statens legemiddelverk, 2009.
10. Legemiddelforbruket i Norge 2004-2010. Legemiddelstatistikk 2011, 1. Oslo, Nasjonalt folkehelseinstitutt, 2011.
11. Reseptregisteret 2004-2010. www.reseptregisteret.no/ (9.2.2012).
12. WHO Collaborating Centre for Drug Statistics Methodology. ATC index with DDDs 2011. Oslo, WHO Collaborating Centre, Oslo, 2010.
13. Hetlevik I, Holmen J, Krüger O et al. Fifteen years with clinical guidelines in the treatment of hypertension-still discrepancies between intentions and practice. Scand J Prim Health Care 1997, 15, 134-40.
14. WHO Collaborating Centre for Drug Statistics Methodology. www.whocc.no/ (9.2.2012).
15. Fretheim A, Håvelsrud K, MacLennan G et al. The effects of mandatory prescribing of thiazides for newly treated, uncomplicated hypertension, interrupted time-series analysis. PLoS Med 2007, 4, e232.
16. Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients, cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354, 1751-6.
17. Hansson L, Lindholm LH, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension, the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353, 611-6.
18. Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension, the Nordic Diltiazem (NORDIL) study. Lancet 2000, 356, 359-65.
19. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA), a multicentre randomised controlled trial. Lancet 2005, 366, 895-906.
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensinconverting enzyme inhibitor or calcium channel blocker vs diuretic, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002, 288, 2981-97.
21. Thoenes M, Neuberger HR, Volpe M et al. Antihypertensive drug therapy and blood pressure control in men and women, an international perspective. J Hum Hypertens 2010, 24, 336-44.
22. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension, is it a wise choice? Lancet 2004, 364, 1684-9.
23. Graff-Iversen S, Jenum AK, Grøtvedt L et al. Risikofaktorer for hjerteinfarkt, hjerneslag og diabetes i Norge. Tidsskr Nor Lægeforen 2007, 127, 2537-41.